Emalex Biosciences raises $250 million to treat stuttering and Tourettes By: Chicago Business Journal via Business Journals November 03, 2022 at 10:41 AM EDT Emalex Biosciences announced it closed a $250 million Series D funding round this week. Read More >> Related Stocks: Harbor Disruptive Innovation ETF